PDS, a clinical-stage biotech owns a novel nanotechnology platform vector that has demonstrated eradication of aggressive cancers in preclinical studies.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free